AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
BABA   261.01 (-0.22%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
BABA   261.01 (-0.22%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
BABA   261.01 (-0.22%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
AAPL   383.68 (+0.25%)
MSFT   213.67 (-0.30%)
FB   245.07 (+0.23%)
GOOGL   1,539.01 (+1.34%)
AMZN   3,200.00 (+0.55%)
NVDA   419.17 (-0.28%)
CGC   17.42 (+8.74%)
BABA   261.01 (-0.22%)
MU   50.70 (+1.44%)
GE   6.69 (+1.67%)
TSLA   1,544.65 (+10.78%)
AMD   55.88 (-2.41%)
T   30.13 (+2.00%)
ACB   12.02 (+2.12%)
F   6.10 (+4.27%)
GILD   76.32 (+2.15%)
DIS   119.34 (+2.16%)
BAC   24.02 (+5.49%)
NFLX   548.73 (+8.07%)
BA   178.44 (+2.98%)
Log in

NASDAQ:EVLOEvelo Biosciences Stock Price, Forecast & News

$4.40
-0.10 (-2.22 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.30
Now: $4.40
$4.52
50-Day Range
$3.59
MA: $4.35
$5.16
52-Week Range
$3.01
Now: $4.40
$9.27
Volume58,700 shs
Average Volume106,023 shs
Market Capitalization$142.27 million
P/E RatioN/A
Dividend YieldN/A
Beta1
Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815, which are in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of atopic dermatitis, asthma, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases. The company is also involved in developing EDP150, a monoclonal microbial candidate, which is in Phase 1/2 clinical study for the treatment of colorectal cancer, triple-negative breast cancer, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. Evelo Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Read More
Evelo Biosciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.25 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EVLO
CUSIPN/A
Phone617-577-0300

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.88 per share

Profitability

Net Income$-85,470,000.00

Miscellaneous

Employees75
Market Cap$142.27 million
Next Earnings Date8/4/2020 (Estimated)
OptionableNot Optionable

Receive EVLO News and Ratings via Email

Sign-up to receive the latest news and ratings for EVLO and its competitors with MarketBeat's FREE daily newsletter.

Evelo Biosciences (NASDAQ:EVLO) Frequently Asked Questions

How has Evelo Biosciences' stock been impacted by COVID-19 (Coronavirus)?

Evelo Biosciences' stock was trading at $4.37 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EVLO stock has increased by 0.7% and is now trading at $4.40. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Evelo Biosciences?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Evelo Biosciences.

When is Evelo Biosciences' next earnings date?

Evelo Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Evelo Biosciences.

How were Evelo Biosciences' earnings last quarter?

Evelo Biosciences Inc (NASDAQ:EVLO) issued its quarterly earnings data on Monday, May, 11th. The company reported ($0.71) EPS for the quarter, beating analysts' consensus estimates of ($0.73) by $0.02. View Evelo Biosciences' earnings history.

What price target have analysts set for EVLO?

5 brokers have issued 12-month price targets for Evelo Biosciences' stock. Their forecasts range from $6.00 to $17.00. On average, they expect Evelo Biosciences' stock price to reach $10.33 in the next twelve months. This suggests a possible upside of 134.8% from the stock's current price. View analysts' price targets for Evelo Biosciences.

Has Evelo Biosciences been receiving favorable news coverage?

Media stories about EVLO stock have been trending negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Evelo Biosciences earned a news sentiment score of -2.4 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news about Evelo Biosciences.

Are investors shorting Evelo Biosciences?

Evelo Biosciences saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 1,810,000 shares, an increase of 8.4% from the June 15th total of 1,670,000 shares. Based on an average daily trading volume, of 81,100 shares, the days-to-cover ratio is presently 22.3 days. Currently, 15.6% of the company's stock are short sold. View Evelo Biosciences' Current Options Chain.

Who are some of Evelo Biosciences' key competitors?

What other stocks do shareholders of Evelo Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evelo Biosciences investors own include AbbVie (ABBV), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Obseva (OBSV), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Arbutus Biopharma (ABUS), Apellis Pharmaceuticals (APLS) and Ardelyx (ARDX).

Who are Evelo Biosciences' key executives?

Evelo Biosciences' management team includes the following people:
  • Dr. Noubar B. Afeyan Ph.D., Co-founder & Chairman (Age 56)
  • Dr. Balkrishan Gill, Pres, CEO & Director (Age 54)
  • Dr. Mark Bodmer, Chief Scientific Officer and Pres of R&D (Age 61)
  • Dr. Duncan McHale M.D., Ph.D., Chief Medical Officer (Age 52)
  • Mr. Jonathan Poole, CFO & Treasurer (Age 44)

When did Evelo Biosciences IPO?

(EVLO) raised $85 million in an IPO on Wednesday, May 9th 2018. The company issued 5,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets served as the underwriters for the IPO and JMP Securities was co-manager.

What is Evelo Biosciences' stock symbol?

Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO."

How do I buy shares of Evelo Biosciences?

Shares of EVLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Evelo Biosciences' stock price today?

One share of EVLO stock can currently be purchased for approximately $4.40.

How big of a company is Evelo Biosciences?

Evelo Biosciences has a market capitalization of $142.27 million. The company earns $-85,470,000.00 in net income (profit) each year or ($2.67) on an earnings per share basis. Evelo Biosciences employs 75 workers across the globe.

What is Evelo Biosciences' official website?

The official website for Evelo Biosciences is www.evelobio.com.

How can I contact Evelo Biosciences?

Evelo Biosciences' mailing address is 620 Memorial Drive Suite 500 West, Cambridge MA, 02139. The company can be reached via phone at 617-577-0300 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.